Avanos Medical (AVNS) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" AVNS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVNS, but not buy additional shares or sell existing shares.
View AVNS analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12-month price targets for Avanos Medical's stock. Their AVNS share price forecasts range from $28.00 to $34.00. On average, they anticipate the company's share price to reach $31.00 in the next twelve months. This suggests a possible upside of 53.2% from the stock's current price.
View analysts price targets for AVNS or view top-rated stocks among Wall Street analysts.

Avanos Medical's stock was trading at $27.06 at the start of the year. Since then, AVNS stock has decreased by 25.2% and is now trading at $20.24.
View the best growth stocks for 2023 here.

Avanos Medical saw a increase in short interest during the month of August. As of August 15th, there was short interest totaling 805,800 shares, an increase of 6.8% from the July 31st total of 754,800 shares. Based on an average daily volume of 255,400 shares, the days-to-cover ratio is currently 3.2 days. Approximately 1.8% of the company's stock are short sold.
View Avanos Medical's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our AVNS earnings forecast.

Avanos Medical, Inc. (NYSE:AVNS) released its earnings results on Wednesday, August, 9th. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.34 by $0.10. The business earned $169.40 million during the quarter, compared to analysts' expectations of $186.30 million. Avanos Medical had a positive trailing twelve-month return on equity of 5.49% and a negative net margin of 4.61%. The firm's revenue was down 16.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.41 earnings per share.

Invesco S&P SmallCap Health Care ETF holds 119,434 shares of AVNS stock, representing 1.06% of its portfolio.

Avanos Medical issued an update on its FY23 earnings guidance on Wednesday, August, 9th. The company provided earnings per share guidance of $1.05-$1.15 for the period, compared to the consensus earnings per share estimate of $1.52.

32 employees have rated Avanos Medical Chief Executive Officer Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among the company's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Pfizer (PFE), Procter & Gamble (PG), Johnson & Johnson (JNJ), RTX (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVNS stock can currently be purchased for approximately $20.24.

Avanos Medical (NYSE:AVNS) has a market capitalization of $948.71 million and generates $818.50 million in revenue each year. The company earns $50.50 million in net income (profit) each year or ($0.78) on an earnings per share basis.

The company employs 4,044 workers across the globe.

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The official website for the company is avanos.com. The company can be reached via phone at (844) 428-2667 or via email at investor.relations@avanos.com.